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Similar to normal stem cells, tumor-
initiating cells are regulated extrinsically
within their microenvironment. Lau et al.
find that cancer-associated fibroblasts
play a crucial role in the regulation of liver
T-ICs through HGF-mediated activation
of the c-Met/FRA1/HEY1 cascade.
Targeting this pathway may be a
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Like normal stem cells, tumor-initiating cells (T-ICs)
are regulated extrinsically within the tumor microen-
vironment. Because HCC develops primarily in the
context of cirrhosis, in which there is an enrichment
of activated fibroblasts, we hypothesized that can-
cer-associated fibroblasts (CAFs) would regulate
liver T-ICs. We found that the presence of a-SMA(+)
CAFs correlates with poor clinical outcome. CAF-
derived HGF regulates liver T-ICs via activation
of FRA1 in an Erk1,2-dependent manner. Further
functional analysis identifies HEY1 as a direct down-
stream effector of FRA1. Using the STAMNASH-HCC
mouse model, we find that HGF-induced FRA1 acti-
vation is associated with the fibrosis-dependent
development of HCC. Thus, targeting the CAF-
derived, HGF-mediated c-Met/FRA1/HEY1 cascade
may be a therapeutic strategy for the treatment
of HCC.INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common and
deadliest malignancies worldwide. The poor prognosis of HCC is
attributed to its resistance to chemotherapy and its high rate of
recurrence. Increasing evidence shows that tumor-initiating cells
(T-ICs), which are capable of tumor initiation, self-renewal, differ-
entiation, and chemoresistance, are responsible for treatment
failure and tumor relapse. In HCC, several liver T-IC markers
have been identified, including CD13, CD24, CD44, CD47,
CD90, CD133, and the epithelial cell adhesionmolecule (Haragu-
chi et al., 2010; Lee et al., 2011, 2014; Yang et al., 2008b; Ma
et al., 2007; Yamashita et al., 2009). However, the regulation ofCe
This is an open access article undliver T-ICs within the tumor microenvironment remains unclear.
T-ICs are regulated by both intrinsic and extrinsic signals (Ma
et al., 2007; Korkaya et al., 2011) that are generated by the tumor
microenvironment. Therefore, a better understanding of how the
properties of liver T-ICs are regulated by the tumormicroenviron-
ment could lead to the development of a novel therapeutic strat-
egy for targeting liver T-ICs.
Tumor cells are embedded in a complex tumor microen-
vironment composed of various types of stromal cells, including
fibroblasts, inflammatory cells, endothelial cells, and bone
marrow-derived cells (Li et al., 2007; Tlsty and Coussens,
2006). Cancer-associated fibroblasts (CAFs) are among the ma-
jor cell populations within the stromal compartment, and acti-
vated fibroblasts are the pre-dominant form of CAFs found in
several malignancies. CAFs are best known for their prominent
role in tumor development through secretion of tumor-support-
ive growth factors and nutrients to mediate cancer growth and
metastasis (Mazzocca et al., 2010). More than 80% of HCC
cases develop within the context of cirrhosis, which is always
accompanied by an enrichment of activated fibroblasts due to
chronic inflammation (Luedde and Schwabe, 2011). Despite
increasing evidence revealing the supportive function of CAFs
in HCC, the role of CAFs in regulating liver T-IC properties re-
mains unknown.
To examine the potential role of CAFs in the regulation of liver
T-ICs, we isolated, characterized, and propagated CAFs in vitro
from fresh HCC clinical samples. We found that CAFs enriched
the population of liver T-ICs through paracrine secretion, which
could be augmented by the reciprocal interaction between
CAFs and HCC cells. Using cytokine profiling, hepatocyte
growth factor (HGF) was found to be the most potent mediator
of this effect in conditioned medium (CM); this was confirmed
by blocking the activation of the HGF/c-Met pathway using an
HGF-neutralizing antibody or a c-Met kinase inhibitor. Further-
more, we identified FRA1 as an important mediator of HGF/
c-Met-induced T-IC regulation via direct Erk phosphorylation.ll Reports 15, 1175–1189, May 10, 2016 ª 2016 The Authors 1175
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Clinical Significance and Charac-
terization of CAFs Isolated from Freshly
Resected HCC Samples
(A) Representative IHC image showing two HCC
cases with low a-SMA expression and high a-SMA
expression.
(B) Pictures of two batches of CAFs, derived
from two HCC specimens, taken under a light
microscope. The images show their fibroblast
morphology in vitro.
(C–E) As assessed by (C) flow cytometry or (D and
E) IF staining, the established CAFs showed (C and
D) positive expression for the fibroblast markers
a-SMA and FAP and (C and E) negative expression
for the epithelial markers pan-cytokeratin and AFP
and the endothelial marker CD31.By using the STAM non-alcoholic steatohepatitis (NASH)-HCC
mouse model, we found that HGF-induced FRA1 activation
was associated with fibrosis-dependent HCC development.
Further RNA sequencing (RNA-seq) analysis identified HEY1,
a downstream target of the Notch pathway, as a direct down-
stream effector of FRA1. FRA1/HEY1 overexpression was signif-
icantly correlated with poor patient survival. Our findings may
provide an attractive therapeutic approach for targeting the
CAF-derived, HGF-mediated c-Met/FRA1/HEY1 cascade to
achieve better clinical outcomes for HCC patients.
RESULTS
Isolation, Characterization, and Clinical Significance of
CAFs in HCC
CAFs with alpha-smooth muscle actin (a-SMA) expression are
considered the main cellular constituents of stroma in a number
of cancers (Micke and Ostman, 2005). To understand the role of
CAFs in HCC, we evaluated their clinical significance by
analyzing the a-SMA expression in 47 HCC patients using immu-
nohistochemical (IHC) staining (Figure 1A). Patients whose
tumors had a-SMA overexpression had significantly shorter dis-
ease-free survival rates (p = 0.04, log rank test). To understand
the functional roles of CAFs in HCC, we isolated CAFs from fresh1176 Cell Reports 15, 1175–1189, May 10, 2016HCC clinical samples. We minced HCC
tissues into small pieces and cultured
them in vitro, and the culture medium
was replenished once every 2 days. After
2–3 weeks of incubation, CAFs that had
attached to the culture plate started to
grow out; other cell types became unat-
tached and were removed through
washing. We then characterized and
confirmed the fibroblast identity of the
CAFs isolated from the HCC specimens.
We found that all CAFs that were es-
tablished and grew in vitro had a ho-
mogenous spindle-shaped fibroblastic
morphology (Figure 1B). We analyzed
markers of activated fibroblasts, inclu-
ding a-SMA and fibroblast activation pro-tein (FAP), to characterize our established CAFs. We found by
flow cytometry analysis that most CAFs displayed positive
expression of a-SMA and FAP (Figure 1C). To exclude potential
contamination of endothelial cells, HCC cells, and other epithe-
lial cells within the isolated CAF populations, we examined the
expression of the respective markers, including CD31, alpha-fe-
toprotein (AFP), and pan-cytokeratin. Contamination by endo-
thelial cells, HCC cells, and other epithelial these cells in the
isolated CAF culture was excluded, as evidenced by 1%
expression of these markers (Figure 1C). This result was
confirmed by immunofluorescence (IF) staining, which showed
positive staining for a-SMA and FAP and negative staining for
CD31, AFP, and pan-cytokeratin (Figures 1D and 1E). Expres-
sion of these markers was found to be comparable after several
passages (data not shown). Based on these results, all CAFs iso-
lated using this method had a fibroblastic phenotype without
contamination of other cell types.
CM of CAFs Regulates Liver T-ICs, an Effect Promoted
by the Stimulation of HCC Cells
To determine whether CAFs play a role in regulating tumorige-
nicity in HCC, we subcutaneously injected HCC cells derived
from patient-derived tumor xenograft #1 (PDTX#1) and PDTX#5
into non-obese diabetic/severe combined immunodeficiency
(NOD/SCID) mice alone, with their corresponding CAFs at a
ratio of 1:1 or 1:3, or with the CM of CAFs. Compared to the
HCC cells injected alone, all groups injected with CAFs or with
theCMofCAFs showed greater tumorigenic potential (Figure 2A;
Table S1). The effect of CAFs on tumorigenicity was more
prominent in HCC cells with CAFs at the ratio of 1:3 when
compared with CAFs at the ratio of 1:1. We found that HCC cells
injected with CAFs or the CM of CAFs had a similar capacity for
enhanced tumorigenicity. These data suggest that CAFs likely
perform their regulatory role in cancer mainly through paracrine
signaling. Therefore, we collected the CM from CAFs for sub-
sequent in vitro experiments to examine the functional role of
the CAFs in regulating the properties of liver T-ICs. To determine
whether the CM of CAFs could regulate the self-renewal of HCC
cells, Bel-7402 andHuh7were subjected to a spheroid formation
assay with supplementation of either DMEM or CM of normal
liver fibroblasts and CAFs. When compared to HCC cells incu-
bated with DMEM and the CM of normal liver fibroblasts, sig-
nificantly more and larger spheroids were observed in HCC cells
incubated with the CM of CAFs (Figure 2B). To confirm the role of
CAFs in maintaining self-renewal, we used a pluripotent mouse
embryonic stem cell (mESC) line. Under feeder-free conditions,
mESCs are maintained as a self-renewing and pluripotent
population in the presence of leukemia inhibitory factor (LIF) in
the culture medium (Liu et al., 2013). Upon LIF withdrawal,
mESCs undergo spontaneous differentiation. We found that
the withdrawal of LIF for 48 hr resulted in a decrease in the
expression of Nanog and Klf4, and this effect was reversed in
the presence of the CM of CAFs (Figure S1). To investigate
whether the CM of CAFs could enrich the T-IC population in
HCC cells, we measured by flow cytometry the expression of
three liver T-IC markers, CD44, CD47, and CD90, in CM-treated
HCC cells (Lee et al., 2014; Yang et al., 2008b). We found that
the CM of CAFs enhanced the percentage of populations of
these markers in HCC cells (Figure 2C). Specifically, for CD44,
we found that CD44s was upregulated in both Bel-7402 and
Huh7 cells upon incubation with the CM of CAFs, while
CD44v6 was only induced in Bel-7402 cells (data not shown).
Using Annexin V/phosphatidylinositol (PI) staining, Huh7 cells
and Bel-7402 cells treated with either cisplatin or doxorubicin
showed a lower percentage of apoptotic cells when incubated
with the CMof CAFs (Figure 2D). Several reports have suggested
that T-ICs possess a high metastatic potential (Lee et al., 2011;
Yang et al., 2008a). Consistent with these findings, both Bel-
7402 and Huh7 cells displayed greater migration and invasion
abilities when they were incubated with the CM of CAFs (Fig-
ure 2E) and epithelial mesenchymal transition (EMT) was
induced (data not shown). Several studies have also demon-
strated that tumor cells can educate stromal cells in promoting
tumor development (Erez et al., 2010). To examine whether
HCC cells educate CAFs to enhance their potential to regulate
liver T-ICs, we incubated CAFs with CM collected from Huh7
cells. We found that the CM of educated CAFs (st-CAFs) had a
greater ability to promote the self-renewal of HCC cells when
compared to the CM of CAFs without education (Figure 2F).
This result demonstrated that CAFs could promote liver T-IC
properties and, in turn, HCC cells could educate CAFs to in-
crease their potential.HGF in the CM of CAFs Regulates Liver T-ICs
To identify the key secretory protein in CAFCM thatmediates the
self-renewal-promoting effect on HCC cells, we compared the
cytokine profiles of the CM from Huh7 cells, CAFs, and Huh7-
stimulated CAFs by cytokine array (Figure S2A). We found that
ten cytokines were identified to be preferentially secreted by
CAFs and seven of these were produced upon stimulation by
Huh7 cells. These seven factors were interleukin-6 (IL-6), HGF,
GCP-2, MCP-1, MCP-2, MCP-3, and RANTES (Figure S2B).
The effect of these cytokines on the in vitro self-renewal ability
of HCC cells was investigated. Bel-7402 and Huh7 cells were
subjected to a spheroid formation assay and supplemented
with these seven cytokines at both 10 and 100 ng/ml; HGF
was the most potent cytokine in stimulating spheroid formation
of HCC cells (Figure S2C). Using ELISA, we found that both
CAFs secreted HGF and that this effect was enhanced by
stimulation with Huh7 (Figure S2D), confirming the results of
the cytokine array profiling. Based on this finding, we turned
our attention toward HGF and characterizing its functional role
in regulating liver T-ICs. We found that all examined HCC cell
lines produced no or negligible levels of HGF, while all CAFs pro-
duced a significant amount of HGF, which suggests that CAFs in
the tumor stroma are a major source of HGF (Figure 3A). This
in vitro finding was confirmed in HCC clinical samples showing
a positive correlation between the mRNA expression of HGF
and the CAF marker ACTA2 (which encodes for the a-SMA
protein) in our HCC clinical samples (R = 0.7995, p < 0.0001,
Pearson correlation) (Figure 3B). To demonstrate that c-Met
phosphorylation is due to CAF-derived HGF but not due to
HCC itself in an autocrine manner, we first evaluated the activa-
tion status of c-Met by assessing phosphorylation at tyrosine
residues 1234 and 1235 in a panel of HCC cell lines. Western
blotting results showed that in most HCC cell lines, excluding
MHCC-97L and MHCC-97H, tyrosine residues 1234 and 1235
of c-Met were not auto-phosphorylated; the phosphorylation
event was only observed when these HCC cells were incubated
with exogenous HGF (data not shown). To investigate the func-
tional role of CAF-derived HGF in regulating T-ICs, we evaluated
the self-renewal ability of T-ICs in vitro by administering recom-
binant HGF at a level comparable to that secreted by CAFs
(2 and 10 ng/ml). At this dosage, we found that HGF resulted in
increased c-Met phosphorylation at tyrosine residues 1234 and
1235 in Huh7 and Bel-7402 cells (Figure 3C) and promoted the
spheroid formation ability of both cell lines (Figure 3D). We found
minimal effect of HGF on spheroid formation of MHCC-97L cells,
in which tyrosine residues 1234 and 1235 of c-Met were auto-
phosphorylated (data not shown). Using the mESC system
described earlier (Figure S1), we found that HGF exerted an ef-
fect similar to that of the CM of CAFs, which partially restored
the expression of Nanog and Klf4 upon withdrawal of LIF. By
Annexin V/PI staining, Huh7 and Bel-7402 cells treated with
cisplatin or doxorubicin exhibited decrease in the percentage
of the apoptotic population in both cell lines when supplemented
with recombinant HGF (Figure 3E). Similar to incubation with the
CM of CAFs, we found a significant increase in CD44-, CD47-, or
CD90-positive populations after HGF incubation (Figure 3F). In
addition, HCC cells displayed increased migration and invasion
abilities in the presence of recombinant HGF (Figure 3G). ByCell Reports 15, 1175–1189, May 10, 2016 1177
Figure 2. The CM of CAFs Regulates Liver T-ICs
(A) The tumors from PDTX#1 and PDTX#5 were dissociated, and various numbers of tumor cells were subcutaneously injected into the flanks of NOD/SCID mice
alone, with CAFs at a 1:1 or 1:3 ratio, or with the CM of CAFs. HCC cells injected with CAFs or the CM of CAFs formed more and larger tumors when compared
with HCC cells injected alone.
(B) Bel-7402 cells and Huh7 cells were subjected to a spheroid formation assay supplied with DMEM, the CM of normal liver fibroblasts (Normal fibroblast), or the
CM of two batches of CAFs (CAF1 and CAF2). All of them formed significantly more and larger spheroids when supplemented with the CM of CAFs, demon-
strating that the CM of CAFs promoted the self-renewal ability of HCC cells.
(C) The CMof CAFs promoted the expression of liver T-ICmarkers CD44, CD47, andCD90 in HCC cells when comparedwith the groups incubated with the CMof
Normal fibroblast or DMEM only.
(legend continued on next page)
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in vivo tumorigenicity assay, we found that HGF-treated Bel-
7402 and Huh7 cells exhibited greater tumorigenic ability than
did Huh7 cells and Bel-7402 cells alone (Figure 3H; Tables S2A
and S2B). Next, we examined whether exogenous HGF prefer-
entially affected liver T-IC populations by comparing the T-IC
properties between c-Met+ and c-Met populations derived
from Huh7 and Bel-7402 cells. We found that c-Met+ enriched
liver T-IC populations, as evidenced by an increase in the tumor-
igenicity and spheroid formation in c-Met+ cells when compared
with their negative counterparts (Figures 3I and 3J; Tables S2C
and S2D). Finally, we verified the effect of CAF on the regulation
of liver T-ICs through secretion of HGF by blocking HGF/c-Met
activation using an HGF-neutralizing antibody or the c-Met ki-
nase inhibitor PHA-665752. We found that the inhibition of
HGF/c-Met activation using a neutralizing anti-HGF antibody
abrogated the effect of CAF CM on the self-renewal, chemore-
sistance, tumorigenicity, invasiveness, and expression of T-IC
markers (Figure S3; Table S3). A similar phenomenon was
observed when HCC cells were cultured in the presence of
PHA-665752 (Figure S4).
Identification of FOSL1/FRA1 as the Downstream
Effector of HGF/c-Met-Mediated T-IC Regulation
To delineate the molecular mechanism by which HGF regulates
liver T-ICs, we treated Bel-7402 cells with 10 ng/ml of HGF for
18 hr. We then compared the gene expression profile of these
cells to that of untreated control cells by cDNA microarray.
Upon analysis, we identified a list of genes that were upregulated
in response to HGF treatment (Table S4). We focused on FOS-
like antigen 1 (FOSL1) because it showed an upregulation of
2.7-fold upon HGF treatment. We confirmed the upregulation
of the mRNA expression of FOSL1 and protein expression of
FRA1 in Bel-7402 and Huh7 cells following HGF treatment (Fig-
ures 4A and 4B). By western blotting, we also demonstrated
that the CM of CAFs had a similar effect on FRA1 and this effect
was abolished when the CM of CAFs was pre-incubated with
either the HGF-neutralizing antibody or the c-Met inhibitor
PHA-665752 (Figure 4C), confirming that the effect of CAF on
FRA1 was due to the presence of HGF in the CM of CAFs.
Next, we examined whether other AP-1 family members would
be induced by HGF. By qPCR, we found that the expression of
FOSL1 was the most significantly upregulated member of the
AP-1 family, including FOSB, FOSL1, FOSL2, C-FOS, C-JUN,
JUNB, and JUND, in response to HGF treatment (data not
shown), demonstrating that HGF only specifically induced
FOSL1/FRA1 upregulation in the AP-1 family. Furthermore, we
found a positive correlation between the expression of HGF
and that of FOSL1 mRNA in HCC clinical samples (n = 55, R =(D) Bel-7402 and Huh7 cells were treated with the chemotherapeutic drugs cis
fibroblast, or DMEM only and evaluated by Annexin V/PI staining. Both Bel-7402
percentage of Annexin V-positive cells in the presence of the CM of CAFs.
(E) Bel-7402 and Huh7 cells were subjected to migration and invasion assays in th
CM of CAFs promoted the migration and invasion of both cell lines.
(F) Huh7 cells were subjected to a spheroid formation assay in the presence of DM
the number and size of spheroids formed by Huh7 cells.
*p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test, CAF1 or CAF2 versus Normal fi
also Figure S1 and Table S1.0.5303, p < 0.0001, Pearson correlation) (Figure 4D). We then
sought to elucidate the regulatory pathway that mediates HGF-
induced FRA1 upregulation by examining Erk1/2, because they
are known direct downstream mediators of c-Met (Tsukada
et al., 2001). For this purpose, Bel-7402 and Huh7 cells were
pre-treated with 10 mM U0126 to block the Erk1/2 pathway
and then treated with 10 ng/ml of HGF. The inhibition of Erk1/2
abolished HGF-induced FRA1 phosphorylation and upregulation
(Figure 4E). We also found an increase in FOSL1mRNA levels in
the presence of HGF, and this effect was abolished after the
administration of U0126 (Figure 4F). To further understand the
molecular mechanism of how FOSL1 mRNA was upregulated
in the presence of HGF, we performed bioinformatics analysis
using the University of California Santa Cruz Genome Browser.
This analysis found four putative FRA1 binding sites (15,308,
140, 1,137, and 3,664 bp) near the transcription start site of the
FOSL1 promoter (Figure 4G). Therefore, we hypothesized that
FOSL1 was transcriptionally activated by FRA1 in the presence
of HGF. Using a chromatin immunoprecipitation (ChIP)-qPCR
assay, we demonstrated the binding between FRA1 and
FOSL1 promoter in Bel-7402 cells (Figure 4G). These data
suggested that HGF induces Erk1/2 phosphorylation and
subsequent upregulation of FRA1, which leads to the direct
transcriptional activation of FOSL1 in HCC cells to form an
auto-feedback loop.
Clinical and Functional Significance of FRA1 in the
Regulation of Liver T-ICs
To investigate whether FRA1 was the downstream effector of
HGF in regulating liver T-ICs, we successfully knocked down
FRA1 (shFRA1-1 and shFRA1-2) in Bel-7402 and Huh7 cells
using a lentivirus-based knockdown approach under normal
conditions and after HGF treatment (Figure 5A; Figure S5A).
Knockdown of FRA1 decreased the number of spheroids formed
in both HCC cell lines, indicating that FRA1 is important for self-
renewal. In the vector control (shCtl) group, 10 ng/ml of HGF
significantly enhanced the spheroid formation ability of HCC
cells, as demonstrated in Figure 3D, and this effect was
profoundly suppressed upon FRA1 knockdown (Figure 5B;
Figure S5B). Next, we demonstrated that HGF-enhanced che-
moresistance was mediated by FRA1 (Figure 5C; Figure S5C).
To confirm the role of FRA1 in mediating HGF-induced T-IC
regulation, we examined the expression of the liver T-IC markers
CD44 and CD47 in FRA1 knockdown HCC cells with or without
the presence of HGF. FRA1 knockdown not only reduced the
expression of CD44 and CD47 but also abolished HGF induced
by the expression of both CD44 and CD47 in Bel-7402 and Huh7
cells (Figure 5D; Figure S5D). To verify that FRA1 is essential forplatin or doxorubicin in the presence of the CM of CAFs, the CM of Normal
and Huh7 cells exposed to chemotherapeutic drug treatment showed a lower
e presence of the CM of CAFs, the CM of Normal fibroblast, or DMEM only. The
EMonly, CAFCM, or st-CAFCM. CAFCMpromoted and st-CAF CMenhanced
broblast. Data are presented as mean ± SD. Scale bars represent 100 mm. See
Cell Reports 15, 1175–1189, May 10, 2016 1179
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the regulation of liver T-ICs, we compared the mRNA expression
of FOSL1 in sorted CD133+ and CD24+ liver T-ICs to that of their
negative counterparts. We found that FOSL1 was preferentially
expressed in the CD133+ and CD24+ sub-population when
compared to the corresponding CD133 or CD24 cells (Fig-
ure S5E). In addition, we found the effects of HGF-induced
migration and invasion were significantly abolished by FRA1
knockdown (Figure 5E; Figure S5F). Consistent with the preced-
ing in vitro findings, we found that knockdown of FRA1 abolished
the tumor enhancing effect of HGF (Figure 5F; Table S5A).
Finally, we demonstrated the significance of FRA1 in mediating
HGF-induced metastasis using an orthotopic HCC nude mouse
model (Figure 5G). Clinically, FRA1 was frequently detected in
HCC compared to non-tumor tissue. High FRA1 expression
also correlated with reduced disease-free survival (p = 0.01,
log rank test) and overall survival (p = 0.029, log rank test)
(Figure 5I).
Stepwise Increase in the Expression of a-SMA, FRA1,
T-IC Markers, and Secretory HGF during Fibrosis-
Dependent Hepatocarcinogenesis
Becausemost HCC cases develop in a severe fibrotic or cirrhotic
background that is enriched in activated fibroblasts, it would be
interesting to investigate whether HGF-dependent FRA1 activa-
tion is associated with fibrosis-dependent HCC development.
To evaluate the significance of HGF-mediated FRA1 activation
in the regulation of liver T-ICs in fibrosis-dependent hepatocarci-
nogenesis, we employed a STAM NASH-HCC mouse model, in
which HCC develops from liver with fibrosis. We obtained the
plasma and liver tissues from normal-stage, fibrosis-stage, and
HCC-stagemice (Figure 6A). SiriusRedstainingconfirmeddevel-
opment of HCC in fibrotic background (Figure 6B). Using HGF
ELISA, we found stepwise increases in HGF in plasma from the
normal stage to the fibrosis stage and the HCC stage (Figure 6C).
In addition, cytokines that identified in Figure S2B were found by
qPCR analysis to be upregulated in the fibrosis and HCC stages
when comparedwith the normal stage (Figure S6). In parallel withFigure 3. Recombinant HGF Enriches Liver T-IC Populations
(A) CM from a panel of HCC cells and CAFs was collected, and the concentration
low level of HGF (0–100 pg/ml), while all CAFs secreted a significant amount of H
(B) The qPCR results show positive correlation between HGF and ACTA2 levels
(C) Western blot results showing c-Met phosphorylation at tyrosine residues 123
(D) Bel-7402 and Huh7 cells were subjected to a spheroid formation assay in the
number and size of spheroids formed compared to the control.
(E) Bel-7402 and Huh7 cells were treated with the chemotherapeutic drugs cisplat
Annexin V/PI staining. Bel-7402 and Huh7 cells treated with chemotherapeutic d
compared to the DMEM-only control.
(F) The expression of liver T-ICmarkers CD44, CD47, and CD90 was evaluated by
HGF at 2 or 10 ng/ml for 24 hr. Both concentrations of HGF promoted the expre
(G) Both concentrations of HGF promoted the migration and invasion of HCC ce
invaded through the transwell.
(H) Both Huh7 and Bel-7402 cells were subcutaneously injected into NOD/SCIDm
larger tumors compared to tumor cells injected alone. Black arrows on the left flan
represent tumors formed by HGF-treated cells.
(I) Sorted c-Met+ and c-Met HCC cells from Huh7 and Bel-7402 were subjecte
spheroids when compared with their c-Met counterparts.
(J) Sorted c-Met+ and c-Met HCC cells from Huh7 and Bel-7402 were subcutan
indicated by red arrows) formed more and larger tumors compared with their c-M
*p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test. Data are presented asmean ±Sthe changes in the plasma HGF levels, we found a similar step-
wise increase in the expression of Acta2, Fosl1 and increases in
the liver T-IC markers Cd44, Thy1, and Cd24 from the normal to
the fibrosis and HCC stages (Figure 6D). By IF staining and
confocal microscopy analysis, we found that nuclear staining of
FRA1 was absent from normal liver tissue but that FRA1 ex-
pression was induced during fibrosis and enhanced in HCC
(Figure 6E). These results suggested that activated fibroblasts
accumulate during fibrosis, as indicated by Acta2 upregulation,
togetherwith elevatedHGFproduction in themouseHCCmodel.
We then investigated whether activated fibroblasts in cirrhosis
also promoted HCC development through the secretion of HGF
in human HCC specimens. To achieve this goal, we extracted
non-tumor-associated fibroblasts (NFs) from corresponding
non-tumorous liver tissues that were adjacent to HCC but
cirrhotic, and we compared the HGF production and self-
renewal-promoting abilities of these cells to those of CAFs and
normal liver fibroblasts (iBiologics). Consistent with our observa-
tions in themousemodel, normal liver fibroblasts secreted only a
minimal amount of HGF (400 pg/ml), while CAFs and NFs
secreted a significantly greater amount of HGF (3,500–
7,000 pg/ml) (Figure 6F). Furthermore, the CM of CAFs and NFs
promoted spheroid formation ability in HCC cells, while the CM
from normal liver fibroblasts, which did not contain HGF, did
not have this effect (Figure 6G). These data verified that activated
fibroblasts regulate liver T-ICs through the secretion of HGF.
Identification of HEY1 as the Potential Downstream
Effector of FRA1
We subjected FRA1 knockdown (shFRA1-2) Bel-7402 cells and
shCtl to RNA-seq in an attempt to search for the transcriptional
target of FRA1. In the list of genes that were differentially ex-
pressed between the FRA1 knockdown and shCtl groups, we
first screened out the genes with a fragments per kilobase of
exon per million fragments mapped (FPKM) value of less than
0.01 in the shCtl group and then analyzed the expression of
the genes involved in self-renewal pathways, including theof HGF was determined using HGF ELISA. All HCC cells secreted no or a very
GF (850–8,720 pg/ml).
(R = 0.7995, p < 0.0001, Pearson correlation).
4 and 1235 in Huh7 and Bel-7402 cells treated with 2 and 10 ng/ml of HGF.
presence of 2 or 10 ng/ml of HGF. Both concentrations of HGF enhanced the
in and doxorubicin and 2 or 10 ng/ml of recombinant HGF andwere analyzed by
rugs displayed a lower percentage of apoptotic cells in the presence of HGF
flow cytometry from HCC cells that were untreated or treated with recombinant
ssion of liver T-IC markers when compared to the control.
lls, as indicated by an increase in the number of cells that had migrated and
ice alone or with 10 ng/ml HGF. HCC cells injected with HGF formed more and
k represent tumors formed by HCC cells only, while red arrows on the right flank
d to spheroid formation assay. The c-Met+ HCC cells formed larger and more
eously injected into NOD/SCID mice. The c-Met+ HCC cells (right flank, tumors
et counterparts (left flank).
D. Scale bars represent 100 mm. See also Figures S2–S4 and Tables S2 and S3.
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Figure 4. HGFUpregulates FRA1 at Both the
mRNA and Protein Levels
(A) HGF promoted the expression of FOSL1mRNA
in HCC cells. The qPCR results show the mRNA
expression of FOSL1 in Bel-7402 and Huh7 cells in
response to 10 ng/ml of HGF treatment for 5 hr.
The expression of FOSL1 increased 14.6-fold in
Bel-7402 cells and 6.6-fold in Huh7 cells following
HGF treatment. The data are presented as the fold
change relative to the untreated group.
(B) HGF and CAF CM increased the expression of
the FRA1 protein in HCC cells.
(C) The effect of CAF-induced FRAl expression
was abolished by pre-incubation with an HGF-
neutralizing antibody or by the addition of the
c-Met inhibitor PHA-665752 (PHA). a-Tubulin was
used as a loading control.
(D) The qPCR analysis showing the relative mRNA
expression of HGF and FOSL1 in a cohort of 55
HCC clinical samples. The expression levels of
HGF and FOSL1 were positively correlated (R =
0.5303, p < 0.0001, Pearson correlation).
(E) Bel-7402 and Huh7 cells were pre-treated with
U0126 to inhibit Erk1/2, followed by the adminis-
tration of 10 ng/ml of HGF. The administration of
HGF alone promoted both FRA1 activation and
FRA1 expression in HCC cells. Inhibition of Erk1/2
abolished HGF-induced FRA1 activation
(F) The administration of 10 ng/ml HGF increased
the expression of FOSL1, and this effect was
abolished by the administration of U0126.
(G) FRA1 bound to the FOSL1 promoter at putative
binding sites (site 1, 3.0-fold [p = 0.005]; site 2,
1.46-fold [p = 0.017]; site 3, 1.98-fold [p = 0.001];
and site 4, 2.22-fold [p = 0.016]; fold enrichment
normalized to IgG control) proximal to the tran-
scriptional start site in Bel-7402 cells.
**p < 0.01, ***p < 0.001, Student’s t test. Data are
presented as mean ± SD.Wnt, Shh, Notch, and Hippo pathways, that demonstrated more
than 1.5-fold downregulation following FRA1 knockdown (Table
S6A). Because we were searching for the direct transcriptional
target of FRA1, we excluded genes without a FRA1/AP-1 binding
site in their promoter sequence that demonstrated more than
1.5-fold downregulation (Table S6B). By qPCR analysis, we
found that HEY1, an important downstream effector in the Notch
signaling pathway, was the only gene that was consistently
downregulated in both FRA1 knockdown clones in both cell lines
(Table S6C). Downregulation of HEY1 expression in FRA1
knockdown HCC cells was confirmed (Figure 7A). To evaluate
the hypothesis that HEY1 is regulated by FRA1, we transiently
overexpressed FRA1 in Bel-7402 and Huh7 cells (Figure S7A).
The expression of HEY1 mRNA and protein increased upon
FRA1 overexpression (Figures S7B and S7C). To validate the1182 Cell Reports 15, 1175–1189, May 10, 2016transcriptional regulation of HEY1 by
FRA1, we transfected FRA1 stable
knockdown HCC cells with a firefly lucif-
erase construct driven by the HEY1 pro-
moter and performed a luciferase reporter
assay. The firefly luciferase signal wassignificantly reduced in FRA1 knockdown cells compared to
shCtl (Figure 7B). In contrast, the firefly luciferase signal was
significantly higher in cells transiently overexpressing FRA1 (Fig-
ure S7D), demonstrating that HEY1 was regulated transcription-
ally by FRA1. By ChIP assay, we consistently found binding
between FRA1 and the HEY1 promoter in Bel-7402 cells (Fig-
ure 7C). Consistent with the in vitro findings, we observed the
co-localization of HEY1 and FRA1 within the nuclei of HCC cells
in tissue of HCC clinical samples (Figure 7D). This result was re-
inforced by the positive correlation between FOSL1 and HEY1
expression in a cohort of HCC samples (Figure S7E). To examine
whether HEY1 is the downstream effector of FRA1-mediated
T-IC regulation, we overexpressed DDK-HEY1 in FRA1 knock-
down Bel-7402 cells (Figure 7E). Upon FRA1 knockdown, the
number and size of the spheroids formed was greatly reduced,
Figure 5. The Effect of FRA1 on HGF-Mediated T-IC Regulation
(A) By western blot, both shFRA1-1 and shFRA1-2 caused a significant reduction of FRA1 expression when compared to shCtl both under normal conditions and
in response to HGF treatment.
(B) In the shCtl group, HGF increased both the number and the size of spheroids formed by HCC cells. The effect of HGF-induced spheroid formation was
significantly abolished following FRA1 knockdown (shFRA1-1 and shFRA1-2).
(C) FRA1 was knocked down in Bel-7402 cells, and the cells were treated with the chemotherapeutic drug cisplatin in the presence of 10 ng/ml of HGF. Both
shFRA1-1 and shFRA1-2 decreased chemoresistance in HCC cells compared to the shCtl. In the shCtl group, HGF enhanced chemoresistance in HCC cells, as
indicated by the decreased percentage of Annexin V-positive cells. This effect was abrogated upon FRA1 knockdown.
(D) Both shFRA1-1 and shFRA1-2 decreased the expression of CD44 and CD47 with or without the presence of HGF when compared to shCtl.
(E) Knockdown of FRA1 abolished HGF-induced migration and invasion.
(F) Different numbers of shCtl, shFRA1-1, and shFRA1-2 cells were injected subcutaneously into the flanks of NOD/SCID mice alone or with 10 ng/ml HGF. In the
shCtl group, Bel-7402 cells treated with HGF formed more and larger tumors, and this effect was abolished upon FRA1 knockdown.
(G) In an orthotopic HCC metastatic model, HGF induced tumorigenicity and lung metastasis (1/6 versus 4/6) in Bel-7402 cells in vivo, and this effect was
abrogated upon FRA1 knockdown (4/6 versus 0/6 for HGF-treated controls and shFRA1 cells). Tumor volume is shown as a dot plot (NS, not significant).
(H) Representative IHC image showing two HCC cases graded with low FRA1 expression and high FRA1 expression.
(I) Kaplan-Meier survival analysis of disease-free survival and overall survival in HCC cases scored as having either low or high FRA1 expression. High FRA1
expression was significantly correlated with shorter disease-free survival (p = 0.01, log rank test) and overall survival (p = 0.029, log rank test).
*p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test. Data are presented as mean ± SD. Scale bars represent 100 mm. See also Figure S5 and Tables S4 and S5.
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Figure 6. HGF-Dependent FRA1 Activation Is Associated with Fibrosis-Dependent HCC Development
(A) Gross anatomical appearance (upper panel) of the normal-, fibrosis-, and HCC-stage livers from NASH-HCCmodel mice. The histological appearance (lower
panel) at each stage was also analyzed by H&E staining.
(B) Sirius Red staining confirmed the fibrotic background in NASH-HCC model mice.
(C) The level of plasma HGF showed a stepwise increase from normal tissue to fibrotic HCC development (normal = 64 pg/ml versus fibrosis = 250 pg/ml versus
HCC = 360 pg/ml). Data show themean of the plasmaHGF concentrations from twomice in the normal stage and threemice each in the fibrosis and HCC stages.
(D) The mRNA expression of the fibroblast marker Acta2, Fosl1 and liver T-IC markers, including Cd44, Thy1, Prom1, and Cd24, in mice from each stage was
measured by qPCR.
(E) Frozen sections of the livers from normal-, fibrosis-, and HCC-stage mice in the NASH-HCCmouse model were stained with FRA1 antibody (green) and DAPI
(blue) and analyzed by confocal microscopy. A representative confocal image shows FRA1 expression in normal-, fibrosis-, and HCC-stage mice. FRA1
expressionwas barely detectable during the normal stage. Nuclear staining of FRA1 could be observed in the fibrosis stage but showed the greatest expression in
the HCC stage.
(F) The concentrations of HGF in the CM of CAFs (CAF1, CAF2, and CAF3), their paired NFs (NF1, NF2, and NF3), and normal liver fibroblasts were measured
using HGF ELISA. CAFs and NFs secreted a significant amount of HGF into the CM (ranging from 3,500 to 7,000 pg/ml), while normal liver fibroblasts secreted
only a small amount of HGF into the CM (400 pg/ml).
(G) The CMof CAF1 andNF1 enhanced both the number and the size of the spheroids formed by HCC cells compared to the control (DMEMonly) group, while the
CM from normal liver fibroblasts was less potent in promoting spheroid formation in HCC cells compared to CAFs and NFs.
Data are presented as mean ± SD. Scale bars represent 100 mm. See also Figure S6.
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Figure 7. HEY1 Is the Downstream Effector of HGF/c-Met/FRA1 Signaling
(A) The expression of HEY1 was reduced in FRA1 knockdown cells compared to shCtl-treated cells.
(B) The firefly luciferase signal was significantly lower in FRA1 knockdown cells, demonstrating that HEY1 promoter activity was suppressed following FRA1
knockdown. The data are presented as the fold change relative to the shCtl group.
(C) FRA1 bound to HEY1 promoter at putative binding sites (site 1, 1.925-fold [p = 0.0003]; site 2, 2.675-fold [p = 0.009]; site 3, 2.367-fold [p = 0.002]; and site 4,
2.233-fold [p = 0.005]; fold enrichment normalized to IgG control) proximal to the transcriptional start site in Bel-7402 cells.
(D) Frozen sections of a human HCC specimen were stained with DAPI (blue), HEY1 antibody (red), and FRA1 antibody (green) and analyzed by confocal
microscopy. Co-localization of HEY1 and FRA1 was apparent.
(E) DDK-HEY1 was overexpressed in FRA1 knockdown Bel-7402 cells. Western blot analysis confirmed the overexpression of DDK-HEY1 in FRA1 knockdown
Bel-7402 cells, as indicated by the additional band for DDK-HEY1 on top of the endogenous HEY1 protein.
(F) FRA1 knockdown reduced the number and size of the spheroids formed, and this inhibitory effect was partially rescued by HEY1 overexpression.
(G) The shCtl, FRA1 knockdown (shFRA1-2), and HEY1-overexpressing FRA1 knockdown (HEY1-shFRA1) Bel-7402 cells treated with 10 ng/ml of HGF were
injected subcutaneously into the flanks of NOD/SCID mice. The inhibitory effect of FRA1 knockdown on tumorigenicity was greatly recovered by HEY1 over-
expression.
(H) High HEY1 expression was significantly correlated with shorter disease-free survival (p = 0.028, log rank test) and overall survival (p = 0.008, log rank test).
*p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test. Data are presented as mean ± SD. Scale bars represent 100 mm. See also Figure S7 and Tables S5–S7.
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and this inhibitory effect wasmostly recovered upon overexpres-
sion of HEY1 (Figure 7F). Moreover, we investigated the effect of
HEY1 recovery on the tumorigenicity of FRA1 knockdown HCC
cells in vivo. We found that the inhibition of tumorigenicity
upon FRA1 knockdown was greatly restored by HEY1 overex-
pression (Figure 7G; Table S5B). Lastly, we retrospectively
analyzed the HEY1 expression in 79 HCC patients by qPCR.
The cutoff value of T/NR 4was used to determineHEY1 expres-
sion in HCC patients. Patients whose tumors had high HEY1
expression were associated with microsatellite formation (p =
0.044, chi-square test), and direct liver invasion (p = 0.007,
Fisher’s exact test) (Table S7). Patients whose tumors had
HEY1 overexpression had significantly shorter overall and dis-
ease-free survival rates than did those with lowHEY1 expression
(p = 0.008 and p = 0.028, respectively, log rank test).
DISCUSSION
CAFs have been shown to support HCC progression by
enhancing tumor cell proliferation and invasiveness (Mazzocca
et al., 2010), but the role of CAFs in regulating liver T-IC prop-
erties remains unclear. To address this issue, we isolated CAFs
from fresh HCC clinical specimens and investigated their func-
tional role in regulating liver T-ICs. CAFs have been shown to
be activated fibroblasts in many cancers (Orimo et al., 2005).
Several markers that are preferentially expressed by activated
fibroblasts, including a-SMA, FAP, desmin, and fibroblast-spe-
cific protein, have been widely and commonly used to isolate
and identify CAFs in human malignancies. CAFs comprise a
heterogeneous population of cells in terms of function and
origin (Augsten et al., 2010). However, in our study, we found
that 99.8% of the isolated CAFs were a-SMA positive and
100% were FAP positive; these findings demonstrated that
the main population of CAFs isolated from HCC consists of
activated fibroblasts. To eliminate the possibility of contamina-
tion by epithelial cells and endothelial cells, we stained the CAF
cultures for the endothelial cell, HCC cell, and epithelial cell
markers of CD31, AFP, and pan-cytokeratin, respectively; the
CAF culture did not contain any cells expressing these markers.
These data demonstrated that we had successfully isolated
CAFs from our clinical HCC specimens, established them in
an in vitro culture, and characterized their fibroblastic identity.
CAFs are known to secrete various types of growth factors, cy-
tokines, and proteases that directly act on tumor cells or other
stromal cells to create a tumor-permissive environment. For
example, Orimo et al. (2005) showed that CAFs promoted
breast tumor growth and angiogenesis through the secretion
of SDF-1. In this study, we demonstrated that CAFs, as cellular
components within the tumor stroma, exerted a T-IC-promoting
effect in HCC through paracrine secretion. However, we uncer-
tain of whether there is an effect when HCC cells are mixed
with other cell populations within the tumor stroma, including
endothelial cells. Lu et al. (2013) previously demonstrated the
role of the CM of endothelial cells in the regulation of T-ICs in
colorectal cancer. HCC cells stimulate CAFs to become more
potent in promoting the self-renewal of liver T-ICs. Tumor cells
are known to actively modify and influence the tumor stroma to
create a tumor-supportive niche. It has been reported that can-1186 Cell Reports 15, 1175–1189, May 10, 2016cer cells can secrete several types of growth factors, such as
IL-6 or transforming growth factor b1, to activate or stimulate
CAFs, leading to their activation and the secretion of tumor-
promoting growth factors (Giannoni et al., 2010; Mazzocca
et al., 2010).
By cytokine array, we identified HGF as the most prominent
CAF-derived cytokine in promoting HCC self-renewal. Aberrant
HGF/c-Met activation has been reported in many cancers,
including HCC, in which overexpression of HGF has been asso-
ciated with a poor prognosis (Xie et al., 2013). Using HGF
ELISA, we found that HCC cell lines do not secrete HGF, while
CAFs secrete a significant amount of HGF. Consistently, we
observed that HCC cells do not show auto-activation of
c-Met, which could only be activated by the CM of CAFs con-
taining CAF-derived HGF. c-Met is the only receptor of HGF,
which was found to be mainly expressed in epithelial cells
such as cancer cells (Comoglio et al., 2008). Based on this
observation, the effect of CAF-derived HGF on other cell types
within the tumor microenvironment is not obvious. The
emerging role of the HGF/c-Met pathway in regulating cancer
stemness also has been revealed in a few studies. In pancreatic
cancer, c-Met was found to be a marker for pancreatic T-ICs,
and c-Methigh cells readily formed spheroids in vitro. The acti-
vation of the HGF/c-Met pathway was found to increase T-IC
properties in other cancers by triggering EMT, Wnt signaling,
and Notch signaling (Sigurdsson et al., 2011; Vermeulen
et al., 2010). By a cell-sorting approach, we found that
c-Met+ populations enhanced liver T-IC populations, as evi-
denced by increased abilities in self-renewal and tumorige-
nicity. In addition, a similar effect in self-renewal was observed
in the presence of the CM of CAFs. This result highlights the
role of CAF-derived HGF in the regulation of liver T-ICs. We
found that physiological levels of recombinant HGF in CAFs en-
riched liver T-IC populations, as evidenced by an increase in
tumorigenicity, self-renewal, chemoresistance, and the expres-
sion of T-IC markers. The use of an HGF-neutralizing antibody
or the c-Met inhibitor PHA-665752 efficiently neutralized CAF-
derived HGF and blocked c-Met activation, thereby abolishing
the induction of the HGF/c-Met pathway and the subsequent
effect on T-IC properties. This result supports the therapeutic
potential of the use of the HGF-neutralizing antibody and
c-Met inhibitor for treatment of HCC.
By cDNA microarray profiling analysis, we identified FOSL1/
FRA1 as a potential downstream effector of HGF. FRA1 is a
member of the FOS family (c-FOS, FOSB, FRA1, and FRA2),
members of which bind to the JUN-family proteins (c-JUN,
JUNB, and JUND) to form the AP-1 transcription factor com-
plex. The divergent and specific functionalities of AP-1 pro-
teins have also been reported. For example, Grigoriadis et al.
(1993) showed that transgenic mice overexpressing c-FOS
developed osteosarcomas but mice expressing FOSB or
c-JUN did not. Such findings suggest that every AP-1 protein
has a specific role and that family members are not function-
ally redundant. In our study, HGF treatment of HCC cells spe-
cifically promoted the expression of FRA1 but not other AP-1
family members, indicating that the specific function of FRA1
is required to mediate the effects of HGF in HCC. By western
blot analysis, we found that HGF significantly upregulated
FRA1 expression and activated FRA1 by phosphorylation
through Erk1/2; this effect was abolished by the administration
of an Erk inhibitor. The emerging role of FRA1 in regulating
cancer stemness has also been reported in breast cancer
(Tam et al., 2013). By generating FRA1 knockdown cells, we
confirmed that FRA1 is crucial for mediating the effects of
HGF on liver T-IC properties. These in vitro findings were veri-
fied by the clinical observation that high FRA1 expression
correlated with poorer cellular differentiation in human HCC.
In addition, FRA1 overexpression was significantly correlated
with poor survivals in HCC patients.
We used the STAM NASH-HCC mouse model to investigate
whether FRA1 activation is involved in fibrosis-dependent hepa-
tocarcinogenesis. We found that HGF, the activated fibroblast
marker Acta2, Fosl1, and liver T-IC markers concurrently
increased stepwise from the normal stage to the fibrosis stage
and eventually to the HCC stage. This study indicated that the
generation and maintenance of stem-like pre-malignant cells
are necessary to drive hepatocarcinogenesis. Given the func-
tional significance of FRA1 in promoting liver T-IC properties
and its positive association with liver T-IC marker expression in
fibrotic hepatocarcinogenesis, HGF-induced FRA1 activation
during liver fibrosis may be crucial in supporting the growth of
tumor progenitors. We demonstrated that fibroblasts from the
fibrotic liver also secrete a significant amount of HGF and
promote the self-renewal of HCC cells. Our data provide
evidence that FRA1 activation, which is probably induced
by the secretion of HGF from activated fibroblasts that accumu-
late during fibrosis, is associated with fibrosis-dependent
hepatocarcinogenesis.
We compared the gene expression profiles of FRA1 knock-
down (shFRA1-2) and shCtl Bel-7402 cells by RNA-seq. We
showed that HEY1, which contains an AP-1 binding sequence
near its promoter sequence, was downregulated at the mRNA
and protein levels following FRA1 knockdown in both HCC cell
lines. The HEY1 transcription factor is a canonical downstream
effector gene in the Notch signaling pathway (Harrison et al.,
2010). However, only a few reports have investigated the specific
role of HEY1 in regulating these cells. In pancreatic cancer, the
expression of HEY1 was found to be higher in the DCLK1HI
T-IC subpopulation than in its more differentiated counterpart
(Bailey et al., 2014). In HCC, the ectopic expression of HEY1 pro-
moted HCC tumorigenicity (Jia et al., 2011). The overexpression
of HEY1 in FRA1 knockdown cells reversed the reduction in self-
renewal and tumorigenesis upon FRA1 knockdown, suggesting
that HEY1 is a downstream effector of FRA1 in the regulation
of T-ICs. We then demonstrated a direct interaction between
FRA1 andHEY1 by ChIP assays. This in vitro finding was verified
in vivo, showing the co-localization of the HEY1 and FRA1 pro-
teins in the nuclei of HCC cells in clinical HCC samples.
In summary, we identified c-Met/FRA1/HEY1 signaling in the
CAF-derived, HGF-mediated regulation of liver T-ICs. Our re-
sults provide a better understanding of how liver T-ICs are regu-
lated in the tumormicroenvironment and reveal a potential target
that could be used for the development of more effective the-
rapeutic strategies in HCC. Further investigation of comparing
therapeutic inhibition between traditional HGF/c-Met and
c-Met/FRA1/HEY1 is awaited.EXPERIMENTAL PROCEDURES
Patient Samples
Primary HCC and corresponding adjacent non-tumor liver tissues were ob-
tained from patients at Queen Mary Hospital, Pamela Youde Nethersole
Eastern Hospital, and Queen Elizabeth Hospital in Hong Kong. All tissue spec-
imens were snap-frozen in liquid nitrogen and stored at 80C or formalin
fixed and paraffin embedded for IHC study. The use of human samples was
approved by the Institutional Review Board of the University of Hong Kong
and the Hospital Authority Hong Kong.
Cell Lines and Cell Culture
The human HCC cell lines Huh7 and HLE were obtained from the Japanese
Cancer Research Bank. Bel-7402, SMMC-7721, and PLC-8024 were obtained
from the Shanghai Institutes for Biological Sciences, Chinese Academy of
Sciences. Hep3B, SNU-182, and HepG2 were purchased from the American
Type Culture Collect (ATCC). MHCC-97L, MHCC-97H, and MHCC-LM3
were provided by Liver Cancer Institute, Fudan University, China. The immor-
talized normal liver cell line, MIHA, was kindly provided by Dr. J.R. Chowdhury,
Albert Einstein College of Medicine, New York. 293FT cells were purchased
from Invitrogen. The mESC line D3 was purchased from ATCC. Normal liver
fibroblasts were purchased from iBiologics.
Isolation and In Vitro Establishment ofCAFs andNFs fromFreshHCC
Samples
Fresh HCC samples and their corresponding non-tumor counterparts were
washed with serum-free DMEM/F-12 medium and finely minced into small
pieces of approximately 0.2 3 0.2 mm. The minced samples were incubated
in fresh culture medium for 24 hr to allow attachment to the culture plate.
Following incubation, the unattached cells were removed, and the remaining
cells were allowed to grow on the plate for 2–3 weeks. In this period, the me-
dium was replenished once every 2 days until the fibroblasts started to grow
out. The fibroblasts were checked for >90% positive staining for the fibroblast
markers a-SMA and FAP and negative staining for the endothelial cell marker,
HCC cell marker, and epithelial cell marker (CD31, AFP, and pan-cytokeratin,
respectively) to make sure that there was no contamination of other cell types
before the cells were subjected to experiments. The fibroblasts isolated from
tumor tissue were defined as CAFs, and those isolated from the non-tumor
counterpart were defined as NFs. CAFs and NFs with no more than ten pas-
sages were used for experiments.
In Vivo Tumorigenicity Experiments
The study protocol was approved by and performed in accordance with the
Committee of the Use of Live Animals in Teaching and Research at The Univer-
sity of Hong Kong. Various numbers of HCC cells resuspended in 50 ml medium
mixed with 50 ml Matrigel Matrix (BD Biosciences) were injected subcutane-
ously into the flanks of NOD/SCID mice. Mice were sacrificed within 5 months
post injection, at which time tumors were harvested. T-IC frequency was
calculated using the Extreme Limiting Dilution Analysis (ELDA) software (Hu
and Smyth, 2009) with 95% CI. For examining the in vivo tumorigenicity of
HCC cells derived from PDTXs, HCC cells of various cell numbers alone or
together with CAFs at a ratio of 1:1 or 1:3, or with the CM of CAFs were
subcutaneously injected into the flanks of NOD/SCID mice as described
above. For CM of CAFs groups, the cells were resuspended in 50 ml CAF
CM instead of medium, and 50 ml CAF CM was supplemented once every
2 days for a total of 3 rounds by injecting into the site of tumor engraftment.
Collection of CM
CAFs, NFs, normal liver fibroblasts, or HCC cells were seeded on six-well
plates at 13 105 cells per well density. Culture medium was removed 24 hr af-
ter cell seeding, cells were washed once with PBS, and 1 ml of serum-free me-
dium was added per well. After 24 hr of incubation at 37C, the CM was
collected and passed through a 0.2 mm membrane syringe filter to remove
any cells and cell debris.
For neutralization of HGF in the CM of CAFs, CM was pre-incubated with
10mg/mlof humanHGFantibodyor its immunoglobulinG (IgG) control (R&DSys-
tems) for 1 hr at room temperature before it was subjected to experimental use.Cell Reports 15, 1175–1189, May 10, 2016 1187
Mouse Models
The STAM NASH-HCC mouse model was developed by and purchased from
Stelic Institute & Co., and HCC was developed from the NASH background.
The liver tissues and plasma from two normal mice of the same strain
(C57BL/6J) and 8 weeks of age were acquired from the Animal & Plant Care
Facility of the Hong Kong University of Science and Technology to serve as
controls.
Patient Sample Processing and Development of PDTX
Fresh HCC samples were dissociated by the gentleMACS dissociator (Milte-
nyi) in the presence of 20 mg/ml DNaseI (Roche) and 4 mg/ml liberase (Roche).
The viability of the cells was evaluated by trypan blue staining (Sigma-Aldrich).
Then, 1 3 106 live cells were resuspended, mixed with Matrigel Matrix (BD
Biosciences) at a 1:1 ratio, and subcutaneously injected into the flanks of
NOD/SCID mice. The tumor developed from the mice was regarded as the
PDTX. A number was assigned for each PDTX specific to the patient from
whom the tumor was resected.
Statistical Analysis
The statistical significance of the results obtained for the dual-luciferase re-
porter assay, ChIP-qPCR, qPCR, spheroid formation assay, flow cytometry
analysis, invasion and migration assays, and in vivo tumor formation assay
was determined by Student’s t tests using Microsoft Office Excel software.
The results are shown as the means and SDs, and p values of less than 0.05
were considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).
Pearson’s correlation analysis was used to determine the correlations among
HGF, ACTA2, FOSL1, and HEY1 expression using Prism 6 software (v.6.04,
GraphPad). Pearson’s chi-square test and Fisher’s exact test were used to
assess the correlations between clinicopathological parameters and FRA1
or HEY1 expression. Kaplan-Meier survival analysis was used to analyze dis-
ease-free survival and overall survival, and the statistical significance was
calculated by log rank test; these analyses were carried out using SPSS 17.
Additional experimental procedures are provided in the Supplemental
Information.
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